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ABSTRACT

treatment goals. Because T2DM is a progressive

Introduction: The treatment of type 2 diabetes

disease, the requirement for combination
treatment escalates over time, driving the need

mellitus (T2DM) continues to pose challenges

for therapies with complementary mechanisms

for clinicians and patients. The dramatic rise in
T2DM prevalence, which has paralleled the rise

of action.
Methods and Results: Online public resources

in obesity, has strained the healthcare system
and prompted the search for therapies that not

were searched using ‘‘empagliflozin’’, identifying
32 articles in PubMed, and 12 abstracts

only effectively treat hyperglycemia, but are

presented at the 2013 American Diabetes

also weight neutral or promote weight loss. In
most clinical situations after diagnosis, patients

Association meeting. Peer-reviewed articles
and abstracts describing preclinical studies and

are advised to adopt lifestyle changes and
metformin is initiated to help control blood

clinical trials were retrieved, and relevant
publications included in this review. Trials

glucose levels. However, metformin may not be

registered on clinicaltrials.gov were searched

tolerated, or may not be sufficient for those
with higher glucose levels at diagnosis. Even

for ongoing empagliflozin studies.
Conclusion: The sodium–glucose co-transporter

among those who have initial success with
metformin, the majority eventually require

2 (SGLT2) inhibitors are of great interest since
they provide a novel, insulin-independent

one or more additional agents to achieve their

mechanism of action. The SGLT2 inhibitor
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empagliflozin has demonstrated promising
pharmacodynamic and pharmacokinetic properties.
In clinical trials, empagliflozin has demonstrated
a good efficacy and safety profile in a broad
range of patients with T2DM, and appears to be
an attractive adjunct therapeutic option for the
treatment of T2DM. Ongoing trials, including
patients with T2DM and comorbidities such as
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hypertension,

provide

pharmacotherapy at diagnosis [4]. Metformin is

important additional data, which will further
define the role of empagliflozin in a growing

are

expected

to

recommended as initial therapy with addition

movement toward individualized approaches to
diabetes care.
Keywords: Add-on therapy; Clinical trials;
Empagliflozin; Fasting plasma glucose; Glucose
excretion; Glycosylated hemoglobin (HbA1c);
Sodium–glucose co-transporter 2 (SGLT2)
inhibitor; Type 2 diabetes mellitus (T2DM)

of sulfonylureas, thiazolidinediones, dipeptidyl
peptidase (DPP)-4 inhibitors, glucagon-like
peptide-1 (GLP-1) receptor agonists, sodium–
glucose co-transporter 2 (SGLT2) inhibitors, or
insulin as needed [4]. These agents have
different mechanisms of action, and different
effects on insulin resistance, insulin secretion, and
weight. Therefore, the risk/benefit ratio of each
drug, or drug combination, needs consideration in
light of therapeutic goals and potential safety

INTRODUCTION

concerns for individual patients [4].
Of these different classes of anti-diabetes

Type 2 diabetes mellitus (T2DM) is a chronic
disease characterized by elevated blood glucose

drugs, the SGLT2 inhibitors are the newest.
These agents help regulate blood glucose levels

levels,
insulin
insufficiency of

by blocking the reuptake of filtered glucose in

resistance,
and
relative
insulin production. The

prevalence of T2DM is rising dramatically

the proximal tubule, leading to significant
excretion of glucose via the urine, which is a

around the world. For example, in the United
States (US) the number of adults with diabetes

novel and insulin-independent approach
(Fig. 1) [5]. Clinical experience with SGLT2

increased by 75% during the time between a
survey conducted during 1988–1994 to a second

inhibitors has increased since the approvals of
dapagliflozin [in November 2012 by the

survey in 2005–2010 [1]. In the US, as

European Medicines Agency (EMA) and in

elsewhere, this increase is generally seen in
parallel with the rise in the prevalence of

January 2014 by the US Food and Drug
Administration (FDA)] and canagliflozin (in

obesity, which is now at epidemic proportions
[1, 2]. The total economic burden associated

March 2013 by the FDA and November 2013
by the EMA). A third agent, empagliflozin, is in

with diabetes treatment and lost productivity is

late-stage clinical trials in a global development

substantial; in the US alone, these costs have
been calculated at 245 billion USD for 2012 [3].

program, including the US and Europe. In this
review, the available data from these trials,

After diagnosis, treatment for T2DM is
initially focused on lifestyle management and

along with preclinical studies, are surveyed to
determine the potential value of empagliflozin

includes
changes
in
dietary
choices,
consumption patterns, and the institution of

in the treatment of patients with T2DM.

exercise regimens to reduce weight, enhance

REVIEW METHODS

insulin sensitivity, and lower blood glucose
levels [4]. If these strategies do not achieve the
desired goals for blood glucose [or if at diagnosis
a patient’s glycosylated hemoglobin (HbA1c)
level is [7.5%], then guidelines recommend

During November 2013, PubMed (US National
Library of Medicine, Bethesda, MD, USA) and
the Scientific Sessions Online Resources
(American Diabetes Association, Alexandria,
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Fig. 1 Key agents and sites of action for type 2 diabetes mellitus drugs. DPP dipeptidyl peptidase, GI gastrointestinal, GIP
gastric inhibitory polypeptide, GLP glucagon-like peptide, SGLT2 sodium–glucose co-transporter 2
VA, USA) were searched using the term

contribute

‘‘empagliflozin’’, identifying 32 articles in
PubMed, and 12 clinical abstracts presented at

humans [6]. This active compound was
eventually identified as phlorizin and it was

the

Association

established that increased glucose excretion

meeting. Peer-reviewed articles and abstracts
describing preclinical studies and clinical trials

could help regulate blood glucose levels [6].
Early studies showed that phlorizin inhibited

were retrieved, and relevant publications
included in this review. The reference lists of

the transport of glucose in a variety of tissues,
including the kidney and small intestine [7, 8].

relevant

for

Further investigation identified phlorizin as a

potential additional reports. Trials registered
on clinicaltrials.gov were searched for ongoing

competitive inhibitor of the SGLT1 and SGLT2
proteins, which are membrane-embedded

empagliflozin studies, using the search term
‘‘empagliflozin’’ and the criteria ‘‘Phase 3’’. The

proteins responsible for reabsorption of
glucose from the glomerular filtrate in the

analysis in this article is based on previously

kidney. SGLT1 is also found in the small

conducted studies, and does not involve any
new studies of human or animal subjects

intestine, where it is responsible for absorption
of glucose and galactose.

performed by the author.

In a diabetic rat model, phlorizin treatment
increased glucose concentration in urine, and

Discovery and Brief History of SGLT
Inhibitors

normalized plasma glucose levels in the absence

For over a century, a naturally occurring
botanical glucoside has been known to

[9]. While these properties made phlorizin very
interesting, it was ultimately unsuitable for

2013

American

Diabetes

publications

were

reviewed

to

glucosuria

in

animals

and

of hypoglycemia, in both fasting and fed states
[9]. Phlorizin also improved insulin sensitivity
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clinical development for several reasons. Firstly,
phlorizin is broken down in the gastrointestinal
tract, and must thus be administered
intravenously; secondly, the active metabolite,
phloretin, is a potent inhibitor of facilitative
glucose transporters; and thirdly, phlorizin is
associated

with

frequent

gastrointestinal

adverse events (AEs) including diarrhea and
dehydration [10]. Although these events are
usually attributed to
selectivity for SGLT2

phlorizin’s limited
over SGLT1 (and

Table 1 Summary of key pharmacokinetic parameters of
empagliﬂozin 10 mg and 25 mg at steady-state after oral
dosing
Pharmacokinetic
parameters

Empagliﬂozin dose
10 mg qd
(n 5 8)

25 mg qd
(n 5 9)

AUC0–t,ss (nmol h/L)

2,030 (362)

4,990 (1,080)

Cmax,ss (nmol h/L)
tmax,ss (h)

a

283 (90.1)

630 (106)

1.5 (1.0–2.0)

2.0 (0.7–4.2)

t1/2,ss (h)

14.3 (2.4)

10.7 (2.1)

consequent presence of unabsorbed glucose

Fe0–24,ss (%)

18.7 (4.5)

12.7 (6.4)

and galactose in the large intestine), early
studies with dual SGLT1/2 inhibitors suggest

CLR,

34.4 (7.9)

23.5 (8.7)

SGLT1 inhibition is not inevitably associated
with gastrointestinal AEs [11]. Nevertheless, it
was clear that phlorizin was not suitable for
further development, but did serve as a basis for
the identification of inhibitors with improved
safety and tolerability profiles.
Empagliflozin Pharmacological
Characteristics and Mechanistic Studies

t,ss

(mL/min)

Data are mean (SD) unless otherwise indicated
AUC area under concentration–time curve, Cmax
maximum plasma concentration, CLR renal clearance, Fe
fraction of dose that was excreted unchanged in urine, qd
once daily, SD standard deviation, ss steady state, t dosing
interval, t1/2 terminal half-life in plasma, tmax time to
maximum plasma concentration
a
Median (range). Data are shown for the proposed
therapeutic doses (empagliﬂozin 2.5 mg and 100 mg were
also tested; for details, please see Heise et al. [12])

Extensive drug discovery and development

empagliflozin is a C-glucoside, and the carbon–
carbon bond between the glucose and aglycone

studies

10773

moieties makes it resistant to gastrointestinal

(empagliflozin; 1-chloro-4-[b-D-glucopyranos-1yl]-2-[4-([S]-tetrahydrofuran-3-yl-oxy)-benzyl]-

degradation, allowing oral administration [5].
The pharmacokinetic and pharmacodynamic

benzene; Fig. 2) as a potent and selective
competitive inhibitor of the SGLT2 protein.

(PK/PD) attributes of empagliflozin have been
extensively tested in vitro and in vivo, and

Empagliflozin

to

Table 1 shows key parameters for planned

phlorizin; however, while phlorizin is an
O-glucoside and thus susceptible to degradation

therapeutic doses, 10 mg and 25 mg [12]. Early
studies included analysis of cell lines, stably

by b-glucosidase in the gastrointestinal tract,

over-expressing human (h) SGLT1, SGLT2, or
SGLT4 receptors, which were screened for

in

vitro

is

identified

structurally

BI

related

specific cellular uptake of a radiolabeled test
molecule [14C]-alpha-methyl glucopyranoside.
In addition, two new cell lines over-expressing
hSGLT5 and hSGLT6 were established, and the
binding kinetics of [3H]-labeled empagliflozin
were also analyzed [13]. Taken together, these
Fig. 2 Chemical structure of empagliﬂozin

studies demonstrated that empagliflozin is a
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potent inhibitor of hSGLT2, with a half

oral ingestion, with a median time to maximum

maximal inhibitory concentration (IC50) of

plasma concentration (tmax) of approximately

3.1 nM, and has [2,500-fold selectivity for
inhibition of SGLT2 versus SGLT1 [13].

1.5–2.1 h, and total drug exposures were
generally proportional with escalating doses.

Subsequent in vivo pharmacological studies
confirmed that empagliflozin lowered blood

Empagliflozin also demonstrated a biphasic
decline in plasma concentrations during the

glucose levels and improved glycemic control

decay phase, with a terminal elimination half-

in diabetic rodent models, with dose-dependent
increases in urinary glucose excretion (UGE)

life ranging from 8.6 to 13.1 h [17].
In these healthy volunteers, the rate of UGE

[14]. In addition, 5 weeks of empagliflozin
treatment reduced HbA1c levels by 0.3% and

increased with escalating doses, and reached a
plateau around the 50-mg dose. The mean total

1.1% with 1 or 3 mg/kg, respectively, compared

amounts of glucose excreted in the urine during

with an increase of 1.1% in vehicle-treated
animals. Improved insulin sensitivity was also

24 h after administration of empagliflozin (0.5,
2.5, 10, 25, 50, 100, 200, 400, and 800 mg) were

recorded with empagliflozin [14].
The metabolic response to empagliflozin

3.1, 30.6, 47.9, 56.5, 63.6, 78.6, 69.1, 90.8, and
61.6 g, respectively, versus 0.06 g with placebo

has been studied in patients with T2DM [15].

[17]. The amounts of glucose excreted in the

As predicted from the theory of glucotoxicity,
reduction of blood glucose with empagliflozin

urine were similar under fed and fasted
conditions, indicating food had no clinically

was associated with improvements in
measures of insulin resistance and beta-cell

relevant effects on drug absorption. In these
healthy volunteers, empagliflozin had a good

function. The investigators also observed an
unexpected increase in endogenous glucose

safety profile and was well tolerated: reported
AEs included headaches, nervous system and

production,

an

gastrointestinal disorders; all were reported at

increase in plasma glucagon levels [15]. It
has been suggested that combination therapy

possibly

resulting

from

similar frequencies in empagliflozin and
placebo-treated subjects, and none were

with an agent that inhibits glucagon by
increasing incretins (a GLP-1 mimetic or

dose-dependent. There was one report of
hypoglycemia, which was observed 3 h after

DPP-4 inhibitor) may give synergistic effects

an oral glucose tolerance test. Since the

for the treatment of hyperglycemia, but this
work is still at early stages, and additional

glucose levels showed mild hypoglycemia
(53 mg/dL), it was considered to be reactive

studies are needed [16].

hypoglycemia, and therefore not related to
study drug [17].

Empagliflozin Phase I Studies in Humans:

Similar results were seen in another Phase I

Safety, Tolerability, and Pharmacokinetics

study of empagliflozin doses ranging from 1 to
100 mg in 48 healthy Japanese men [18].

Phase I studies of single doses of empagliflozin
were conducted in a study of 72 healthy male

Empagliflozin was rapidly absorbed in these
subjects, with a tmax of 1.25–2.50 h, after which

volunteers recruited at a single clinic in
Germany. Subjects were randomized to an

plasma concentrations declined with classic

empagliflozin dose of 0.5–800 mg, or placebo

biphasic kinetics. Empagliflozin exposures
were proportional to doses studied. At the

[17]. Empagliflozin was quickly absorbed after

highest doses tested (100 mg), mean UGE was
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and

UGE

was

dose-

the impact of renal impairment on the PK/PD

Empagliflozin

was

again

well

profile of a single dose of empagliflozin 50 mg

tolerated, with no reports of hypoglycemia in
any of the subjects [18].

[20]. In patients with renal impairment, peak
plasma concentrations of empagliflozin were

Following
these
results
in
healthy
volunteers, a study of empagliflozin safety,

similar to those with normal renal function. In
comparison to patients with normal renal

tolerability, and PK/PD was conducted over

function, total plasma exposure (area under

28 days in patients with T2DM [19]. Seventyeight patients received placebo (n = 16) or

the concentration–time curve from zero to
infinity)
and
the
maximum
plasma

empagliflozin once-daily at one of three doses:
10 mg (n = 16), 25 mg (n = 16), or 100 mg

concentration (Cmax) were modestly increased
(Table 2), most likely owing to decreased renal

(n = 30).

approximately
dependent.

74 g

were

clearance of the drug. Patients with mild or

randomized to the 100-mg safety arm of this
study to assess the safety of this high dose of

Twice

moderate renal impairment had slightly
decreased UGE compared with patients with

empagliflozin.
Plasma concentrations of empagliflozin were

normal renal function; those with severe
impairment or renal failure had lower UGE.

dose-dependent over the full range of doses

This suggests that while empagliflozin may be

(10–100 mg) and linear PK were observed [19].
By Day 1, UGE rose from baseline to 74, 90, and

used without dose adjustments in patients with
any degree of renal impairment, reductions in

81 g with increasing doses of empagliflozin (10,
25, and 100 mg, respectively). Elevated UGE

plasma glucose levels would be predicted to be
less clinically meaningful for those with severe

continued
throughout
the
28 days
of
empagliflozin treatment, while virtually no

renal impairment [20].
A related open-label clinical trial, also using a

change in UGE was observed with placebo

single 50-mg dose of empagliflozin, compared

over the same timeframe [19]. Mean daily
plasma glucose and fasting plasma glucose

36 patients with various degrees of hepatic
impairment: eight each with mild [Child–Pugh

(FPG) levels were significantly reduced from
baseline in the empagliflozin groups compared

class A (5–6 points)], moderate [Child–Pugh
class B (7–9 points)], or severe [Child–Pugh class

with the placebo group [19]. The incidence of

C (10–15 points)] hepatic impairment, and 12

AEs was similar, with 50.0, 56.3, and 66.7% of
patients in the empagliflozin 10-mg, 25-mg,

matched controls with normal hepatic function
[21]. Use of SGLT2 inhibitors in patients with

and 100-mg groups, respectively, experiencing
at least one AE versus 62.5% with placebo. The

impaired hepatic function has been an area of
potential concern following a case of liver

most commonly reported AEs were pollakiuria

toxicity with dapagliflozin, although after

(10.3%), nasopharyngitis (9.0%), constipation
(9.0%), and headache (7.7%) [19].

longer follow-up the case was re-classified as
auto-immune hepatitis rather than drug-

Additional trials addressing the safety,
tolerability, and PK/PD of empagliflozin in

induced liver injury, and data from additional
exposure to dapagliflozin have been reassuring

patients

with

as

many

either

renal

patients

hepatic

[22]. In the empagliflozin study, the drug was

impairment have recently been reported. An
open-label trial grouped 40 patients by

or

rapidly absorbed and after achieving peak
concentrations, the expected biphasic decline

estimated glomerular filtration rate to study

in plasma drug concentrations was observed
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Table 2 Empagliﬂozin pharmacokinetics after administration of a single 50-mg dose in patients with renal or hepatic
impairment
Impairment severity

Cmax,ss (nmol/L)

Total plasma exposure
AUC0–? (nmol h/L)

Renal impairment study [20]
Mild (n = 9)

118.2% (96.2, 145.4)

118.8% (93.6, 150.8)

Moderate (n = 7)

119.9% (96.3, 149.5)

102.3% (79.3, 131.9)

Severe (n = 8)

166.3% (134.4, 205.7)

120.7% (94.4, 154.3)

Failure/ESRD (n = 8)

148.3% (119.9, 183.4)

103.8% (81.2, 132.6)

Hepatic impairment study [21]
Mild (n = 8)

123.15% (98.9, 153.4)

103.8% (82.3, 131.0)

Moderate (n = 8)

146.97% (118.0, 183.0)

123.3% (97.7, 155.6)

Severe (n = 8)

174.70% (140.3, 217.6)

148.4% (117.7, 187.2)

For both studies, values are adjusted GMR (impaired/normal group) with 90% CI for adjusted GMR
AUC area under the concentration–time curve, CI conﬁdence interval, Cmax,ss maximum plasma concentration at steady
state, ESRD end-stage renal disease, GMR geometric mean ratio
[21]. PK parameters were mildly elevated, but
were less than twofold the values in patients

T2DM patient population has been tested in a
series of open-label, crossover studies in healthy

with normal hepatic function. While ongoing

volunteers.

vigilance is always prudent, the study
investigators concluded there is no need for

empagliflozin can be given together with the
anti-diabetes drugs metformin or sitagliptin, the

adjustment of empagliflozin doses in patients
with hepatic impairment [21].

commonly prescribed cardiovascular drugs
verapamil, ramipril, and digoxin, and the

These

studies

showed

that

anticoagulant warfarin; in each case without
Empagliflozin: Coadministration
with Other Drugs and Cardiac Safety

the need for dose adjustment for either
empagliflozin or the coadministered drug

Patients with T2DM vary widely in age and

[24–27]. In a similar open-label study, researchers
demonstrated a combined oral contraceptive

often have significant comorbidities, including
advanced cardiovascular disease; therefore, this

ethinylestradiol

30 lg/levonorgestrel

150 lg

patient population often is receiving several

once daily can be coadministered with oral
empagliflozin 25 mg once daily, without

medications concurrently in addition to other
anti-diabetes drugs [23]. Accordingly, any

requirement for dose adjustment [28].
A number of drugs are known to prolong the

potential
adverse
interactions
between
empagliflozin and other commonly prescribed

cardiac QT interval, which can lead to life-

drugs are of clinical interest.
Coadministration with a
clinically
important
drugs

threatening arrhythmias in treated patients
[29]. To assess the cardiac safety of

number of
that
could

empagliflozin, 30 volunteers with a mean age
of 35 years were randomized to a double-blind,

reasonably be expected to be prescribed in the

placebo-controlled study of single doses of
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empagliflozin, 25 and 200 mg (therapeutic and

across all groups was 7.9 ± 0.8%. After 12 weeks,

supratherapeutic, respectively), versus placebo

dose-dependent reductions in HbA1c from

and open-label moxifloxacin 400 mg as positive
control [30]. Within the initial 1–4 h after

baseline were seen in the empagliflozin-treated
patients (5 mg -0.4%, 10 mg -0.5%, 25 mg

empagliflozin dosing, the placebo-corrected
mean change from baseline in the population

-0.6%; p\0.0001 for all doses vs. placebo
?0.1%). Patients in the open-label metformin

heart rate corrected QT interval was 0.6 ms

arm had similar reductions in HbA1c levels of

[90% confidence interval (CI) -0.7, 1.9] for
empagliflozin 25 mg and -0.2 ms (90% CI -1.4,

-0.7%, but the metformin arm was not
designed to be tested for significance against

0.9) for empagliflozin 200 mg. These values are
deemed acceptable since the upper limit of the

the double-blind groups [32].
Among the secondary endpoints, FPG levels

confidence intervals are \10 ms, which is the

also

International Conference on Harmonization
E14 threshold for regulatory concern [31].

-1.29 mmol/L, 10 mg -1.61 mmol/L, 25 mg
-1.72 mmol/L; all doses p\0.0001 vs. placebo

Consistent with the results seen in other trials,
the tolerability of empagliflozin was good for all

?0.04 mmol/L). Of special significance to
patients with T2DM, who tend to be either

study

the

overweight or obese, there were modest but

empagliflozin group experiencing AEs with
empagliflozin compared with 27.6% of the

significant decreases in body weight in each of
the empagliflozin-treated groups, with changes

placebo group.

from baseline of -1.81 kg, -2.33 kg, and
-2.03 kg in the 5, 10, and 25-mg groups,

Empagliflozin in Phase II and Phase III
Clinical Trials

respectively (all p\0.001 vs. placebo); the
open-label metformin group had a -1.32 kg

participants,

with

23.3%

of

decreased

with

empagliflozin

(5 mg

decrease versus baseline [32].
The favorable data emerging from the various
empagliflozin Phase I clinical trials set the stage

The groups had similar rates of AEs, at
32.9% for the placebo group and 29.1% across

for subsequent Phase II and Phase III studies in
various patient populations. While several trials

the empagliflozin groups. Few differences
between groups were observed for the most

are ongoing, a number have already been
reported in the peer-reviewed literature [32–36].

common AEs reported with empagliflozin;

Phase II Trials
In a Phase II, randomized, double-blind,

nasopharyngitis (2.0% vs. 1.2% for placebo)
[32]. There were AEs considered consistent

placebo-controlled clinical trial, the safety,
efficacy, tolerability, and PK of empagliflozin

with urinary tract infections (UTIs) in 4/244

these were pollakiuria (3.3% vs. 0% for
placebo), thirst (3.3% vs. 0% for placebo), and

were evaluated in patients with T2DM [32].

patients (1.6%) on empagliflozin and 1/82
patients (1.2%) on placebo. Genital infections

The investigators randomized 408 patients
(treatment-naı̈ve or having completed a

were reported in five patients (2%) on
empagliflozin versus none on placebo. No

4-week washout) to empagliflozin (5, 10, or
25 mg once daily), placebo, or open-label

patients discontinued due to UTIs or genital

metformin for 12 weeks. At baseline, the
mean ± standard deviation (SD) HbA1c level

infections [32].
A second Phase II study was undertaken to
evaluate the efficacy and safety of empagliflozin

Diabetes Ther (2014) 5:43–63
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as an add-on therapy to metformin. The

after 12 weeks, indicating empagliflozin can be

investigators randomized 495 patients with

efficacious as monotherapy or as add-on

T2DM who were inadequately controlled on
metformin (HbA1c[7% to B10%) to double-

therapy for patients with T2DM who are not
meeting their treatment goals on metformin

blind empagliflozin (1, 5, 10, 25, or 50 mg once
daily) or placebo, or to open-label sitagliptin

alone.

100 mg once daily, in addition to metformin for

Phase III Trials
The Phase III clinical trial program evaluating

12 weeks [33]. At baseline (while on stable
metformin), mean HbA1c across the seven

empagliflozin in patients with T2DM reportedly

groups ranged from 7.8 to 8.1%. After
12 weeks, mean HbA1c increased by 0.15%

includes more than 10 multinational trials,
between them enrolling more than 14,500

in

patients, including patients across a wide age
range and with a diversity of concomitant

the

placebo

group,

compared

with

reductions of -0.1%, -0.2%, -0.6%, -0.6%,
and -0.5% with empagliflozin 1, 5, 10, 25, or

diseases [37]. At the time of writing, three

50 mg, respectively, once daily (all were
significant with the exception of 1 mg

Phase III trials have been published in detail,
and are reviewed below.

empagliflozin) [33]. In addition, empagliflozin

In the first of these Phase III trials, the
efficacy
and
safety
of
empagliflozin

doses of 5–50 mg significantly reduced FPG
levels at 12 weeks, with mean reductions of -2

monotherapy

was

investigated

in

a

to -28 mg/dL compared with an increase of
5 mg/dL with placebo (all p\0.0001).

randomized, placebo-controlled study of
patients with T2DM with HbA1c levels of

Empagliflozin was also associated with body
weight reductions after 12 weeks (-2.3 to -2.9 kg

7–10% who were treatment-naı̈ve or had not
received medication over the 12 weeks

with empagliflozin 5–50 mg vs. -1.2 kg with

preceding

placebo; p\0.01) [33].
In this study, empagliflozin was generally

randomized to empagliflozin 10 mg (n = 224),
empagliflozin
25 mg
(n = 224),
placebo

well tolerated, and reported frequencies of AEs
were similar in the three main treatment

(n = 228), or sitagliptin 100 mg (n = 223) once
daily [34]. Patients with HbA1c[10% at

groups: empagliflozin (29.6–48.6%), placebo

screening were not randomized, but were

(36.6%), and sitagliptin (35.2%), and the
reported rates of hypoglycemia were low and

assigned open-label empagliflozin 25 mg for
24 weeks (n = 87).

balanced among the groups. The most frequent
AEs were UTIs (4.0% vs. 2.8%; empagliflozin vs.

At 24 weeks, the randomized empagliflozin
groups had significant improvements in HbA1c,

placebo) and

FPG, and body weight compared with placebo,

pollakiuria

(2.5%

vs. 1.4%;

the

trial

[34].

Patients

were

empagliflozin vs. placebo). Genital infections
(4.0%) were reported only in the empagliflozin-

as shown in Tables 3,
Furthermore,
patients

treated patients [33].
In these Phase II studies, empagliflozin

empagliflozin were more likely to achieve an
HbA1c target of \7.0% at week 24: among

treatment led to dose-dependent, clinically

patients who had HbA1c levels C7.0% at
baseline, 35% of the empagliflozin 10-mg

meaningful reductions in HbA1c and FPG,
along with concomitant reductions in body
weight compared with placebo-treated patients

4, and 5 [34].
randomized
to

group and 44% of the 25-mg group achieved
HbA1c\7.0% compared with 12% of the
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Table 3 Changes in HbA1c with empagliﬂozin in Phase III clinical trials
Treatment

Baseline mean

Adjusted mean change (95% CI)
versus placebo at 24 weeks

Empagliﬂozin 10 mg qd (n = 224)

7.9 (0.9)a

-0.74% (-0.88, -0.59; p\0.0001)

Empagliﬂozin 25 mg qd (n = 224)

7.9 (0.9)a

-0.85% (–0.99, -0.71; p\0.0001)

a

-0.73% (–0.88, -0.59; p\0.0001)

Monotherapy [34]

Sitagliptin 100 mg qd (n = 223)

7.9 (0.8)

Add-on to metformin [38]
Empagliﬂozin 10 mg qd (n = 217)

7.9 (0.1)b

-0.57% (-0.70, -0.43; p\0.001)

Empagliﬂozin 25 mg qd (n = 213)

7.9 (0.1)b

-0.64% (-0.77, -0.50; p\0.001)

Empagliﬂozin 10 mg qd (n = 225)

8.1 (0.8)a

-0.64% (-0.77, -0.51; p\0.001)

Empagliﬂozin 25 mg qd (n = 216)

a

Add-on to metformin ? sulfonylurea [35]

8.1 (0.8)

-0.59% (-0.73, –0.46; p\0.001)

Add-on to pioglitazone ± metformin [36]
Empagliﬂozin 10 mg qd (n = 165)

8.1 (0.9)a

-0.48% (-0.66, -0.29; p\0.001)

Empagliﬂozin 25 mg qd (n = 168)

8.1 (0.8)a

-0.61% (-0.79, -0.42; p\0.001)

Trials published December 1, 2013. All values are %
CI conﬁdence interval, HbA1c glycosylated hemoglobin, qd once daily, SD standard deviation, SE standard error
a
Baseline mean (SD)
b
Baseline mean (SE)
placebo group (odds ratio for empagliflozin
10 mg vs. placebo: 4.12; 95% CI 2.44, 6.97;

(-2.43 kg; 95% CI -3.50, -1.37) and systolic
blood pressure (-4.0 mmHg; 95% CI -7.1, -0.9)

p\0.0001 and for empagliflozin 25 mg vs.

of a similar level to changes in the empagliflozin

placebo 6.15; 95% CI 3.65, 10.36; p\0.0001).
Both empagliflozin groups also had significant

25-mg randomized group.
The majority of AEs were mild, with similar

reductions from baseline in systolic blood
pressure versus placebo (empagliflozin 10 mg

proportions reported in each treatment arm
[placebo group, 140 (61%); empagliflozin

-2.6 mmHg; 95% CI -4.9, -0.4; p = 0.0231;

10 mg, 123 (55%); empagliflozin 25 mg, 135

empagliflozin 25 mg -3.4 mmHg; 95% CI -5.7,
-1.2; p = 0.0028) [34].

(60%); and sitagliptin, 119 (53%)]. Serious AEs
also occurred in similar proportions of patients

For patients assigned open-label empagliflozin,
no formal statistical analyses were performed, but

[placebo group, 6 (3%); empagliflozin 10 mg,
8 (4%); empagliflozin 25 mg, 5 (2%); and

the investigators noted large reductions from

sitagliptin, 6 (3%)] [34]. The most common AE

baseline to 24 weeks in HbA1c (-3.7%; 95% CI
-4.1, -3.3), with 28% of these patients reaching

was hyperglycemia, which was reported in 35
(15%) placebo patients, five (2%) empagliflozin

HbA1c\7.0% by week 24. The group also had
large reductions in FPG (-4.86 mmol/L; 95% CI

10-mg patients, four (2%) empagliflozin 25-mg
patients, and 13 (6%) sitagliptin patients. The

-5.55, -4.16), and mean changes in weight

second most common AE was nasopharyngitis,
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Table 4 Changes in fasting plasma glucose with empagliﬂozin in Phase III clinical trials
Treatment

Baseline

Change at 24 weeks

Empagliﬂozin 10 mg qd (n = 223)

8.48 (1.79)a

-1.73 (-2.03, -1.43; p\0.0001)b

Empagliﬂozin 25 mg qd (n = 223)

8.47 (1.89)a

-2.01 (-2.31, -1.71; p\0.0001)b

Sitagliptin 100 mg qd (n = 223)

8.16 (1.60)a

-1.04 (-1.34 to -0.73; p\0.0001)b

Empagliﬂozin 10 mg qd (n = 217)

8.60 (0.13)c

-1.11 (0.10); p\0.001 vs. placebod

Empagliﬂozin 25 mg qd (n = 213)

8.29 (0.12)c

-1.24 (0.10); p\0.001 vs. placebod

Placebo (n = 207)

8.66 (0.12)c

?0.35 (0.10)d

Empagliﬂozin 10 mg qd (n = 225)

8.38 (1.82)a

-1.60 (-1.90, -1.30; p\0.001)b

Empagliﬂozin 25 mg qd (n = 216)

8.69 (1.87)a

-1.60 (-1.90, -1.29; p\0.001)b

Empagliﬂozin 10 mg qd (n = 165)

8.44 (2.12)a

-1.30 (-1.71, -0.90; p\0.001)b

Empagliﬂozin 25 mg qd (n = 168)

8.43 (2.05)a

-1.58 (-1.98, -1.18; p\0.001)b

Monotherapy [34]

Add-on to metformin [38]

Add-on to metformin ? sulfonylurea [35]

Add-on to pioglitazone ± metformin [36]

Trials published December 1, 2013. All values are mmol/L; to convert mmol/L to mg/dL multiply by 18.0182
qd once daily, SD standard deviation, SE standard error
a
Baseline mean (SD)
b
Adjusted mean change (95% CI) versus placebo at 24 weeks
c
Baseline (SE)
d
Change from baseline (SE)
which was reported in 17 (7%) placebo patients,
16 (7%) empagliflozin 10-mg patients, 11 (5%)

The safety and efficacy of empagliflozin as
add-on therapy in patients with T2DM

empagliflozin 25-mg patients, and 15 (7%)

receiving

sitagliptin patients. Rates of hypoglycemia
were \1% in all treatment groups [34].

sulfonylurea was assessed in a randomized,
double-blind Phase III trial; two sub-studies

Laboratory measurements included serum
lipids and plasma uric acid concentrations

were defined by the patients’ background
medication at screening. In the first part of the

(Tables 6, 7). Of note, empagliflozin appeared

study,

to be associated with improvements in uric acid
compared with placebo. In addition, compared

randomized to 24 weeks of double-blind
treatment with either empagliflozin 10 mg

with placebo, high-density lipoprotein (HDL)cholesterol increased significantly from baseline

(n = 217) or 25 mg (n = 213) once daily or
placebo (n = 207) [38]. As with the previous

in patients treated with empagliflozin 10 or

trial, patients with HbA1c[10% at screening

25 mg, but levels of total cholesterol, lowdensity lipoprotein (LDL)-cholesterol, or

were not randomized, and instead were
included in an open-label empagliflozin 25-mg

triglycerides did not change [34].

arm (n = 69).

metformin

patients

on

with

or

metformin

without

only

a

were
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Table 5 Changes in body weight with empagliﬂozin in Phase III clinical trials
Treatment

Baseline

Adjusted mean change (95% CI)
versus placebo at 24 weeks

Empagliﬂozin 10 mg qd (n = 224)

78.4 (18.7)a

-1.93 (-2.41, -1.45; p\0.0001)

Empagliﬂozin 25 mg qd (n = 224)

77.8 (18.0)a

-2.15 (-2.63, -1.67; p\0.0001)

Monotherapy [34]

Sitagliptin 100 mg qd (n = 223)

79.3 (20.4)

a

?0.52 (0.04, 1.00; p\0.0355)

Add-on to metformin [38]
Empagliﬂozin 10 mg qd (n = 217)

81.6 (1.3)b

-1.63 (-2.11, -1.15; p\0.001)

Empagliﬂozin 25 mg qd (n = 213)

82.2 (1.3)b

-2.01 (-2.49, -1.53; p\0.001)

Add-on to metformin ? sulfonylurea [35]
Empagliﬂozin 10 mg qd (n = 225)

77.1 (18.3)a

-1.76 (-2.19, -1.34; p\0.001)

Empagliﬂozin 25 mg qd (n = 216)

a

-1.99 (-2.42, -1.56; p\0.001)

Empagliﬂozin 10 mg qd (n = 165)

78.0 (19.1)a

-1.95 (-2.55, -1.36; p\0.001)

Empagliﬂozin 25 mg qd (n = 168)

78.9 (19.9)a

-1.81 (-2.41, -1.22; p\0.001)

77.5 (18.8)

Add-on to pioglitazone ± metformin [36]

Trials published December 1, 2013. All values are kilograms
CI conﬁdence interval, qd once daily, SD standard deviation, SE standard error
a
Baseline mean (SD)
b
Baseline mean (SE)
Preliminary results have been presented, and
support the use of empagliflozin as add-on

empagliflozin groups also had significant
reductions in systolic blood pressure, with

treatment

the

mean changes of -4.5 ± 0.7 mmHg in the

empagliflozin
groups
having
significant
improvements in HbA1c, FPG, and body

10-mg group and -5.2 ± 0.7 mmHg in the
25-mg group.

weight compared with placebo after 24 weeks
(Tables 3, 4, 5) [38]. Among patients who had

For the group of patients with very high
HbA1c at screening, who were assigned open-

to

metformin,

with

HbA1c levels C7.0% at baseline, 13% of the

label empagliflozin 25 mg in addition to their

placebo group achieved an HbA1c\7.0% by
24 weeks compared with 38% of the

background metformin, HbA1c fell by a
mean ± standard error (SE) of -3.2 ± 0.2%

empagliflozin 10-mg group (odds ratio, 4.72;
p\0.001 vs. placebo) and 39% of the

from a baseline mean of 11.1 ± 0.2%.
Improvement was also seen in FPG, with a

empagliflozin 25-mg group (odds ratio, 4.67;

mean ± SE reduction of -3.02 ± 0.57 mmol/L,

p\0.001 vs. placebo). Of note, a weight loss of
[5% of body weight was achieved by 4.8% of

from a baseline mean of 11.30 ± 0.43 mmol/L.
The group also had reductions from baseline

patients in the placebo arm after 24 weeks,
compared with 21.2% on empagliflozin 10 mg,

in body weight (mean ± SE -1.91 ± 0.59 kg)
and systolic blood pressure (mean ± SE

and 23.0% on empagliflozin 25 mg [38]. The

-2.4 ± 1.6).

0.03 (0.04)
0.08 (0.04)
p = 0.377
0.20 (0.05)
p = 0.007

0.00 (0.06)
0.06 (0.06)
p = 0.489
0.06 (0.06)
p = 0.480

[35]a
4.40 (0.07)
4.42 (0.06)
0.06 (0.06)
4.50 (0.07)
0.17 (0.06)
[36]a
4.86 (0.09)
4.76 (0.09)
0.06 (0.09)
4.69 (0.09)
0.06 (0.09)

Add-on to metformin ? sulfonylurea
Placebo (n = 225)
Empagliﬂozin 10 mg qd (n = 225)
Difference vs. placebo
Empagliﬂozin 25 mg qd (n = 216)
Difference vs. placebo

Add-on to pioglitazone ± metformin
Placebo (n = 165)
Empagliﬂozin 10 mg qd (n = 165)
Difference vs. placebo
Empagliﬂozin 25 mg qd (n = 168)
Difference vs. placebo
1.31 (0.02) -0.01 (0.02)
1.28 (0.02) 0.04 (0.02)
0.06 (0.02) p = 0.012
1.31 (0.02) 0.02 (0.02)
0.03 (0.02) p = 0.186

2.76 (0.08)
2.65 (0.08)
0.09 (0.07)
2.60 (0.07)
0.04 (0.07)

0.00 (0.05)
0.09 (0.05)
p = 0.234
0.04 (0.05)
p = 0.576

0.02 (0.04)
0.04 (0.04)
p = 0.807
0.10 (0.04)
p = 0.131

2.90 (0.06)
0.04 (0.04)
2.86 (0.07)
0.06 (0.04)
0.03 (0.06) p = 0.651
2.75 (0.07)
0.11 (0.04)
0.07 (0.06) p = 0.258
2.74 (0.05)
0.03 (0.04)
-0.01 (0.06) p = 0.864

LDL-cholesterol (mmol/L)
Baseline
D from
baseline

1.25 (0.02)
-0.02 (0.01) 2.39 (0.06)
1.26 (0.02)
0.05 (0.01)
2.35 (0.06)
0.06 (0.02) p\0.001
0.01 (0.05)
1.27 (0.02)
0.05 (0.01)
2.41 (0.06)
0.07 (0.02) p\0.001
0.08 (0.05)

1.26 (0.02)
0.04 (0.01)
1.24 (0.02)
0.11 (0.01)
0.07 (0.02) p\0.001
1.25 (0.02)
0.13 (0.01)
0.09 (0.02) p\0.001
1.26 (0.02)
0.02 (0.01)
-0.02 (0.02) p = 0.262

HDL-cholesterol (mmol/L)
Baseline
D from
baseline

Trials published December 1, 2013
D change, HDL high-density lipoprotein, LDL low-density lipoprotein, qd once daily, SE standard error
a
Baseline data are mean (SE), and change from baseline data are adjusted mean (SE)

0.05 (0.05)
0.07 (0.05)
p = 0.738
0.15 (0.05)
p = 0.143
0.08 (0.05)
p = 0.676

5.03 (0.08)
5.00 (0.08)
0.02 (0.07)
5.00 (0.08)
0.11 (0.07)
4.95 (0.07)
0.03 (0.07)

Monotherapy [34]a
Placebo (n = 228)
Empagliﬂozin 10 mg qd (n = 224)
Difference vs. placebo
Empagliﬂozin 25 mg qd (n = 224)
Difference vs. placebo
Sitagliptin 100 mg qd (n = 223)
Difference vs. placebo

Total cholesterol (mmol/L)
Baseline
D from
baseline

Table 6 Changes in serum lipids with empagliﬂozin in Phase III clinical trials

1.73 (0.06) -0.01 (0.06)
1.86 (0.14) -0.18 (0.06)
-0.17 (0.09) p = 0.070
1.76 (0.13) 0.00 (0.06)
0.02 (0.09) p = 0.842

1.70 (0.09) 0.08 (0.09)
1.87 (0.09) 0.03 (0.09)
-0.05 (0.12) p = 0.672
1.82 (0.07) 0.17 (0.09)
0.09 (0.12) p = 0.459

2.01 (0.09) -0.07 (0.10)
2.08 (0.12) -0.30 (0.10)
-0.23 (0.14) p = 0.090
2.37 (0.20) -0.18 (0.10)
-0.11 (0.14) p = 0.408
2.20 (0.13) 0.06 (0.10)
0.13 (0.14) p = 0.350

Triglycerides (mmol/L)
Baseline
D from
baseline
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Table 7 Changes in plasma uric acid with empagliﬂozin in Phase III clinical trials
Treatment

Baseline mean (SD)

Change from
baseline, mean (SD)

Empagliﬂozin 10 mg qd (n = 224)

293 (109)

-58 (80)

Empagliﬂozin 25 mg qd (n = 224)

297 (124)

-62 (83)

Sitagliptin 100 mg qd (n = 223)

298 (114)

?17 (77)

Placebo (n = 228)

307 (133)

-14 (91)

Empagliﬂozin 10 mg qd (n = 225)

314 (127)

-28 (87)

Empagliﬂozin 25 mg qd (n = 216)

298 (115)

-26 (81)

Placebo (n = 225)

307 (110)

?11 (81)

Empagliﬂozin 10 mg qd (n = 165)

286 (116)

-37 (83)

Empagliﬂozin 25 mg qd (n = 168)

272 (116)

-29 (81)

Placebo (n = 165)

275 (113)

?13 (69)

Monotherapy [34]

Add-on to metformin ? sulfonylurea [35]

Add-on to pioglitazone ± metformin [36]

Trials published December 1, 2013. All values are lmol/L; values were normalized to a standard reference range
qd once daily, SD standard deviation. The study of empagliﬂozin as add-on to metformin is not included in this table
because, at the time of writing, it has been published in preliminary form only, and the report did not include uric acid
results
In this trial, AEs were reported by 57.1%,
49.5%, and 58.7% of patients on empagliflozin

10-mg and 25-mg empagliflozin arms vs.
none in patients receiving placebo) [38].

10 mg, empagliflozin 25 mg, and placebo,

In the second part of the study, patients with

respectively.
Hypoglycemia
(defined
as
plasma glucose B70 mg/dL, and/or requiring

HbA1c inadequately controlled on metformin
and a sulfonylurea were randomized to add on

assistance) was
proportions of

low
the

once-daily empagliflozin 10 mg (n = 225),
empagliflozin 25 mg (n = 216), or placebo

the

(n = 225) for 24 weeks [35]. Improvements

empagliflozin 25-mg arm, and 0.5% in the
placebo arm), and none of the cases required

were seen in glycemic control, with reductions
in HbA1c levels after 24 weeks being

assistance [38]. AEs consistent with UTIs were
reported in low proportions across the

significantly greater in the empagliflozintreated groups, as were reductions in FPG and

empagliflozin

reported in very
patients (1.8% in

10-mg

arm,

1.4%

in

treatment arms (5.1%, 5.6%, and 4.9% in the

body weight, as shown in Tables 3, 4, and 5 [35].

empagliflozin 10-mg, 25-mg, and placebo
arms, respectively). Rates of AEs associated

Patients were more likely to achieve
HbA1c\7.0% with empagliflozin, with 26.3%

with genital infection were also low with
empagliflozin, but appeared more frequent

of the empagliflozin 10-mg group reaching this
goal (odds ratio vs. placebo 3.85; 95% CI 2.17,

than with placebo (3.7% and 4.7% in the

6.85; p\0.001) and 32.2% in the empagliflozin
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25-mg group (odds ratio vs. placebo 5.22; 95%

The third Phase III trial published is a

CI 2.95, 9.24; p\0.001). The effects of 24 weeks

randomized, double-blind, placebo-controlled

of empagliflozin on body weight (Table 5) were
consistent with earlier reports, with significant

trial that examined the efficacy and safety of
empagliflozin in patients with T2DM who were

differences in the adjusted means for
empagliflozin versus placebo [35]. Reductions

on pioglitazone at screening; patients could also
be receiving metformin [36]. Patients were

in blood pressure were of a similar level to those

randomized

seen with empagliflozin used as monotherapy,
with a placebo-corrected reduction in the

empagliflozin
10 mg
(n = 165),
25 mg
(n = 168), or placebo (n = 165) for 24 weeks

empagliflozin 10-mg group of -2.7 mmHg
(95% CI -4.6, -0.8; p = 0.005) and in the

[36]. Unlike the aforementioned trials, the
design of this study did not include an open-

and

treated

with

once-daily

25-mg group of -2.1 (95% CI -4.0, -0.2;

label arm for patients with very high HbA1c at

p = 0.032).
In this study, 101 patients with HbA1c[10%

screening.
The investigators found that 24 weeks of

at screening were treated with open-label
empagliflozin 25 mg as add-on to stable

empagliflozin treatment resulted in significant
reductions in HbA1c and FPG (Tables 3, 4), and

metformin and sulfonylurea. The mean ± SE

more patients with HbA1c C7.0% at baseline

change from baseline in HbA1c at week 24 was
-2.9 ± 0.2%, and the mean value fell from

achieved HbA1c\7.0% with empagliflozin
10 mg (23.8%) and 25 mg (30.0%) than with

11.2 ± 1.3% at baseline to 8.2 ± 0.1% at week
24. At week 24, the mean ± SE change from

placebo (7.7%) (odds ratio for empagliflozin
10 mg vs. placebo: 3.85; 95% CI 1.88, 7.92;

baseline in FPG was -3.02 ± 0.37 mmol/L,
change in body weight was -1.76 ± 0.40 kg,

p\0.001; odds ratio for empagliflozin 25 mg vs.
placebo: 5.02; 95% CI 2.49, 10.12; p\0.001).

and change in systolic blood pressure was

Empagliflozin

-4.3 ± 1.2 mmHg.
AEs were reported at similar proportions

significant reductions in body weight (Table 5)
and larger proportions of patients experienced

across treatment groups, at 67.9% in the
empagliflozin 10-mg group, 64.1% in the

reduction of [5% of body weight (18.8% and
13.7% of patients receiving 10 mg and 25 mg of

empagliflozin 25-mg group, and 62.7% in the

empagliflozin, compared with 5.5% of patients

placebo group [35]. Events consistent with UTIs
were reported in 10.3% and 8.3% of the

receiving placebo). Empagliflozin was also
associated with reductions in blood pressure

empagliflozin 10-mg and 25-mg groups,
respectively, versus 8.0% of the placebo group,

compared with placebo: systolic blood pressure
fell by -3.9 mmHg (95% CI -6.23, -1.50;

while events consistent with genital infections

p = 0.001)

were reported in 2.7% and 2.3% of the respective
empagliflozin groups versus 0.9% of the placebo

-4.7 mmHg (95% CI -7.08, -2.37; p\0.001)
with empagliflozin 25 mg [36].

group [35]. For LDL-cholesterol and triglycerides,
there were no significant differences compared

In this study, as in previous studies,
empagliflozin was well tolerated and the

with placebo, while there was a small increase in

incidence of AEs was not significantly different

HDL-cholesterol (Table 6). In the randomized
empagliflozin groups, there were small decreases

from placebo. Similar rates of AEs were reported
in all three treatment arms (67.3%, 71.4%, and

in uric acid (Table 7).

72.7% of patients in the 10-mg, 25-mg, and

was

with

also

associated

empagliflozin

10 mg

with

and
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placebo groups, respectively). Rates of reported

combination therapies. The Phase III studies

hypoglycemia (plasma glucose B70 mg/dL and/

reported above were placebo-controlled, but

or requiring assistance) were also similar across
treatment arms (1.2%, 2.4%, and 1.8% of the

to draw definite conclusions regarding
comparative efficacy, an active-controlled

respective groups), and no patient required
assistance. The proportion of patients with AEs

study is required, and a 4-year Phase III trial of
empagliflozin versus glimepiride is underway

related to UTIs was similar across groups

[39]. Studies are also required to investigate

(17.0%, 11.9%, and 16.4% of patients on
10 mg, 25 mg, and placebo, respectively);

blood pressure profiles in hypertensive patients,
as well as effects in patients with renal

events consistent with genital infection were
seen more commonly with empagliflozin (8.5%,

impairment, and studies in these groups have
reported preliminary data [40, 41]. The

3.6%, and 2.4% of patients on 10 mg, 25 mg,

empagliflozin Phase III program also includes a

and placebo, respectively); however, all were
mild or moderate in intensity and none led to

cardiovascular outcome event trial, enrolling
approximately
7,000
patients
at
high

premature
study
Measurement
of

discontinuation
[36].
serum
lipids
showed

cardiovascular risk [42]. Japanese regulatory
authorities also require a range of trials in

significant increase in HDL-cholesterol in the

Japanese patients, and these are underway.

empagliflozin 10-mg group, but a nonsignificant increase in the 25-mg group

Clearly, the number of clinical trials that are
expected to report in the near future will provide

(Table 6). No significant differences were
reported for total cholesterol, LDL-cholesterol,

a wealth of data on the safety and efficacy of
empagliflozin treatment, to help optimize

or triglycerides in either of the empagliflozin
treatment arms (Table 6). Again, small decreases

treatment regimens for individual patients.

were seen in uric acid levels with empagliflozin,
of approximately the same level seen in the
study of empagliflozin as add-on to metformin

CONCLUSIONS

plus sulfonylurea (Table 7).

Based on the evidence available to date,
empagliflozin appears to have a promising

Anticipated Results: Recently Completed

pharmacologic profile. Pharmacodynamic and
pharmacokinetic characteristics include: (1)

or Ongoing Clinical Trials

very high selectivity for the SGLT2 over SGLT1
The clinical development program for
empagliflozin is at a relatively advanced stage;

receptors, potentially minimizing off-target
effects; (2) predictable pharmacokinetics, and

nonetheless, further Phase II and Phase III
studies are either recently completed or in

no known drug–drug interactions with other
drugs commonly prescribed for this patient

progress,

trials

population; (3) favorable pharmacodynamics,

registered on the US National Institutes of
Health registry at ClinicalTrials.gov are shown

including additive control of plasma glucose
levels via inhibition of reuptake in the kidney,

in Table 8 [43–49]. Given the number of options
available for treatment of T2DM, empagliflozin

with a well-defined dose–response relationship;
(4) a good safety profile, with no increase in

will need to be assessed as add-on therapy to

hypoglycemia compared with placebo; and (5)
acceptable tolerability in all patient populations

and

additional

Phase

III

insulin, among other agents, as well as in initial
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Table 8 Ongoing or recently completed empagliﬂozin Phase III clinical trials
Study population/NCT number

Treatment arms

Add-on to insulin

(1) Empagliﬂozin

NCT01306214 [43]

(2) Placebo

Head-to-head study vs. sulfonylurea

(1) Empagliﬂozin

NCT01167881 [39]

(2) Glimepiride

Head-to-head study vs. DPP-4i

(1) Empagliﬂozin

NCT01984606 [44]

(2) Sitagliptin

T2DM and hypertension

(1) Empagliﬂozin

NCT01370005 [41]

(2) Placebo

T2DM and renal insufﬁciency

(1) Empagliﬂozin

NCT01164501 [40]

(2) Placebo

CV outcome trial

(1) Empagliﬂozin

NCT01131676 [42]

(2) Placebo

Combination with metformin in
treatment-naı̈ve patients

(1) Empagliﬂozin

NCT01719003 [45]

(3) Empagliﬂozin and
metformin

Add-on DPP-4i in patients on
empagliﬂozin and metformin

(1) Empagliﬂozin

NCT01778049 [46]

(3) Empagliﬂozin and
linagliptin

Combination with DPP-4i in patients
on metformin

(1) Empagliﬂozin

NCT01422876 [47]

(3) Empagliﬂozin and
linagliptin

Combination with DPP-4i

(1) Linagliptin

NCT01734785 [48]

(2) Empagliﬂozin and
linagliptin

Add-on to various agents in Japanese
patients

(1) Empagliﬂozin

Enrollment

Duration

Primary outcome measure(s)

52 weeks

Change from baseline in HbA1c

52 and
104 weeks

Change from baseline in HbA1c

834

52 weeks

Change from baseline in HbA1c

825

12 weeks

Change from baseline in HbA1c
and mean 24-h systolic blood pressure

741

52 weeks

Change from baseline in HbA1c

7,000

Up to
8 years

Time to any of CV deatha, nonfatal MI,
and nonfatal stroke

1,397

24 weeks

Change from baseline in HbA1c

690

24 weeks

Change from baseline in HbA1c

1,406

52 weeks

Change from baseline in HbA1c

444

24 weeks

Change from baseline in HbA1c

1,162

52 weeks

Safety (adverse event frequency)

566
1,549

(2) Metformin

(2) Linagliptin

(2) Linagliptin

(2) Metformin

NCT01368081 [49]
Phase III trials returned on a search of ‘ empagliﬂozin’’ at ClinicalTrials.gov on November 29, 2013 are included, if not already reported in the
peer-reviewed literature, and therefore discussed elsewhere in the review. The following studies listed as Phase III studies on ClinicalTrials.gov are
not included: NCT01257334 appears to be a duplicate record for trial NCT01159600, NCT01947855 is a 4-week study with only 60 patients,
and NCT01289990 is a long-term extension study of completed Phase III trials
CV cardiovascular, DPP-4i dipeptidyl peptidase-4 inhibitor, HbA1c glycosylated hemoglobin, MI myocardial infarction, T2DM type 2 diabetes
mellitus
a
Including fatal stroke and fatal MI

studied to date. The most common AEs reported
to date include nasopharyngitis, UTIs, and

favorable, the changes in lipid profiles have
been less consistent between studies—yet it

genital tract infections. Changes in uric acid

must be remembered that these values were

and LDL-cholesterol are of considerable
interest—while the changes in uric acid appear

captured as safety endpoints in the trials, and
thus any potential benefit cannot be defined
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without further studies specifically comparing
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